Protocol No: 2019-1032 
Version No: 10 
Version Date:  August 25, 2023 
1 PROTOCOL TITLE: Validation of a Multi- Parametric Ultra -high Field MRI Protocol for 
Central Nervous System Malignancy ............................................................................................. [ADDRESS_40031] recent 
MRI examination.  ................................................................................................................... 7  
1.3.2  Functional MRI (fMRI) - To assess the typi[INVESTIGATOR_38133].  ......................................................... 7  
1.3.3  To assess the geometric distortion of a radiation planning sequence on a ultra-high 
field (UHF) system.  ................................................................................................................ 7  
2 BACKGROUND  ................................................................................................................ 7  
2.1 Primary brain tumors ...................................................................................................... 8  
2.2 Brain metastasis.  ............................................................................................................. 9  
2.3 Quantitative MRI  .......................................................................................................... 10  
2.4 Multiple B -Value Diffusion Imaging (Adv Diff) ......................................................... 11  
2.5 Chemical Exchange Saturation Transfer (CEST) MRI  ................................................ 12  
2.6 Multiple inversion time (TI) arterial spin labeling (ASL) “Adv ASL” perfusion 
imaging  ...................................................................................................................................... 13  
2.7 Protocol Particular Disease Description  ....................................................................... 13  
3 ELIGIBILITY  ................................................................................................................... 14  
3.1 Inclusion Criteria  .......................................................................................................... 14  
3.2 Exclusion Criteria  ......................................................................................................... 14  
3.3 NUMBER OF PARTICIPANTS  .................................................................................. 15  
4 STUDY PLAN/DESIGN  .................................................................................................. 15  
4.1 Patient Enrollment:  ....................................................................................................... [ADDRESS_40032] Research Institute (HMRI) Registration ....................................... 16  
4.4 MR Scanning: ............................................................................................................... 16  
• Quantitative MRI  .......................................................................................................... 16 
• CEST ............................................................................................................................. 16  
• Adv Diff  ........................................................................................................................ 16  
4.5 Patient  experience survey ............................................................................................. 17  
Proprietary Information of MD Anderson
Protocol No: 2019-1032 
Version No: 10 
Version Date:  August 25, 2023 
2 
 4.5.1  Patients will be given a one-page survey regarding their experience in the 7T MRI 
system following their scan. [Appendix A] .......................................................................... [ADDRESS_40033] of care.  These 
follow- up scans will serve as the basis for statistical analyses that consider treat ment 
response or disease recurrence.  ............................................................................................. 17  
4.7 Conclusion of Study Participation: ............................................................................... [ADDRESS_40034]. ................................................................................................ 17  
4.7.3  Death.  ........................................................................................................................ 17  
5 Image  Analysis.................................................................................................................. 18  
5.1 Lesion  size evaluation:  .................................................................................................. [ADDRESS_40035] diameter after 
appropriate magnification on the pi[INVESTIGATOR_38134] (PACS) monitors. ............................................................................................................................... 18
 
5.1.3  For patients with multiple lesions appropriate for study assessment, the five (5) 
largest lesions will be assessed.  ............................................................................................ 18  
5.2 Lesion CNR evaluation: ................................................................................................ [ADDRESS_40036] imaging 
will be placed and will define the lesion ROI.  ...................................................................... 18  
5.2.2  The ROI mean signal intensity will be recorded. ..................................................... 18  
5.2.3  A mirror ROI will be placed in the contralateral normal-appearing white matter and 
used as the "background" mean signal intensity measurement. ........................................... [ADDRESS_40037] will be used as the “noise” mean signal 
intensity measurement.  ......................................................................................................... [ADDRESS_40038] imaging 
will be placed and will define the lesion ROI.  ...................................................................... 18  
5.3.2  The T1 and T2 tissue weighting that maximizes the ROI mean signal intensity will 
be identified. ......................................................................................................................... 18  
5.3.3  A mirror ROI will be placed in the contralateral normal-appearing white matter and 
used as the "background" mean signal intensity measurement. ........................................... [ADDRESS_40039] will be used as the mean “noise” signal 
intensity measurement.  ......................................................................................................... 18  
Proprietary Information of MD Anderson
Protocol No: 2019-1032 
Version No: 10 
Version Date:  August 25, [ADDRESS_40040] data will be used as the “background” mean signal intensity 
measurement.  ........................................................................................................................ [ADDRESS_40041] will be used as the “noise” mean signal 
intensity measurement.  ......................................................................................................... 19  
5.5 Multiple B Value Diffusion Imaging (Adv Diff) .......................................................... [ADDRESS_40042] imaging 
will be placed and will define the lesion ROI.  ...................................................................... 19  
5.5.2  The AKC for the lesion will be determined using B-values of 0, 1000, and 2000 
mm2/s.  19 
5.5.3  The ADC of the lesion will also be determined using B-values of 0 and 1000 mm2/s.
 19  
5.5.4  A mirror ROI will be placed in the contralateral normal-appearing white matter, and 
"background" AKC and ADC measurement will be measured. ........................................... [ADDRESS_40043] imaging 
will be placed and will define the lesion ROI.  ...................................................................... 19  
5.6.2  This ROI will be used to assess the cerebral blood flow (CBF) from the processed 
ASL data.  .............................................................................................................................. 19  
5.6.3  A mirror ROI will be placed in the contralateral normal-appearing white matter for 
assessment of the “background” CBF. .................................................................................. 19  
5.6.4  This ROI will be used to assess the bolus arrival time (BAT) from the processed 
ASL data.  .............................................................................................................................. 19  
5.7 Task -based fMRI  .......................................................................................................... 20  
5.7.1  fMRI data will be analyzed using custom software, IClinfMRI. .............................. 20  
5.7.2  The general linear model  will be used to generate an activation t -value map for each 
task-based  fMRI data. The model includes the convolution of the task paradigms with a 
canonical hemodynamic response function. ......................................................................... 20  
5.7.3  Significantly activated areas will be determined by [CONTACT_38163] t- value map at 
corrected P  < .05. .................................................................................................................. 20  
5.8 Resting -state fMRI  ........................................................................................................ 20  
5.8.1  Resting -state datasets will be pre-processed through slice timing, motion correction, 
de-spi[INVESTIGATOR_28884], detrending, regressing out covariates (including six motion parameters and two 
Proprietary Information of MD Anderson
Protocol No: 2019-1032 
Version No: 10 
Version Date:  August 25, 2023 
4 
 averaged fluctuations over masks of white matter and cerebrospi[INVESTIGATOR_872]), band- pass 
filtering of 0.01-0.[ADDRESS_40044] and distortion.  ........................................................................................... 20  
5.9.3  The geometric distortion will be evaluated with a full- field geometric distortion 
phantom to assess the geometric accuracy of the SPACE sequence with its specific parameters.  ............................................................................................................................ 20
 
5.9.4  For radiation therapy purposes, the geometric distortion of less than 1mm is desired 
for the typi[INVESTIGATOR_38135] 2 mm is the targeted limit for the useable field of view 20
 
6 Patient Information Confidentiality Plan  .......................................................................... 21  
6.1 Collection of Identifiers:  ............................................................................................... 21  
6.2 Training of personnel: ................................................................................................... 21  
6.3 Data Storage:  ................................................................................................................. 21  
6.4 Data Sharing:  ................................................................................................................ 21  
6.5 Final Disposition of study records: ............................................................................... 22  
7 STATISTICAL CONSIDERATIONS .............................................................................. 22  
7.1 Definitions ..................................................................................................................... 22  
7.1.1  Lesion “ treatment response” will be defined by [CONTACT_38164] 
(CNR).  Treatment response will be assessed only in patients with treatment prior to enrollment.  ............................................................................................................................ 22
 
7.1.2  Disease recurrence will be determined by [CONTACT_38165] (if available) or at 
least three months of imaging follow- up.  Disease recurrence will be assessed only in 
patients with treatment prior to enrollment. Imaging findings will be considered recurrent disease in a les ion if: ............................................................................................................. 22
 
7.2 Overview  ....................................................................................................................... 23  
7.3 Sample Size ................................................................................................................... 23  
7.4 Analysis Plan  ................................................................................................................ 24  
Proprietary Information of MD Anderson
Protocol No: 2019-1032 
Version No: 10 
Version Date:  August 25, 2023 
5 
 8 PROTOCOL MONITORING PLAN  ............................................................................... 24  
9 REFERENCES  ................................................................................................................. 25  
10 APPENDICES  .................................................................................................................. 30  
 
Proprietary Information of MD Anderson
Protocol No: 2019-1032 
Version No: 10 
Version Date:  August 25, 2023 
6 
 PROTOCOL TITLE: Validation of a Multi- Parametric Ultra -high Field MR I Protocol for 
Central Nervous System Malignancy 
 
 Principal Investigator: [INVESTIGATOR_38136] , MD  
 Co-Investigators: Maria Gule, MD, Sujit Prabhu, MD, Jason Stafford, MD, Ho-Ling (Anthony) 
Liu, PhD, Ken Hwang, PhD, Mark Pagel, PhD, Jihong Wang, PhD and Jingfei Ma, PhD ; Dawid 
Schellingerhout, MDMelissa Chen, MD, Frederick Lang, MD, Jeffrey Weinberg, MD, Pi[INVESTIGATOR_38137], PhD, Sherise Ferguson, MD, Jing Li, MD, PhD, Vinay Puduvalli, MD, Clifton Fuller, MD, Abdallah Mohamed, MD, John Slopis, MD , Chirag Patel, MD, Leomar Ballester, MD  
  Statistician: Roland Bassett , Jr. MS.  
 
Outside collaborator:  *Steve H. Fung, MD (Medical Director, MRI Core & Assistant Clinical Member, Research 
Houston Methodist) 
Robert Rostomily, MD (Neurosurgery, Houston Methodist) 
******************** This is an MD Anderson faculty written and supervised research activity. This project is funded 
by [CONTACT_38166]. Only MD Anderson patients will be recruited for enrollment in this study. 
The primary research activity (MRI examination) in this study will take place at the Houston 
Methodist Research Institute.  
*Steve H. Fung, MD, is the Medical Director of the MRI Core at the Houston Methodist 
Research Institute. He will supervise and monitor study activities at the HMRI.  
     
Proprietary Information of MD Anderson
Protocol No: 2019-1032 
Version No: 10 
Version Date:  August 25, [ADDRESS_40045] -to-noise ratio (CNR) for several imaging modalities in brain 
malignancy as compared with normal brain parenchyma separately by [CONTACT_38167].   The methods to be studied include Quantitative MRI 
(T1 and T2 sequencing), Chemical Exchange Saturation Transfer (CEST) MRI, Multiple B-Value Diffusion Imaging (Adv Diff), and Multiple inversion time (TI) arterial spin 
labeling (ASL) perfusion imaging (Adv ASL). 
 
1.[ADDRESS_40046] recent MRI 
examination . 
1.3.2 Functional MRI  (fMRI) - To assess the typi[INVESTIGATOR_38138].  
1.3.3 To assess the geometric distortion of a radiation planning sequence on a ultra -hi gh field 
(UHF ) system . 
 [ADDRESS_40047] shown improvements at 7T over lower field strengths (detailed below). There have additionally been limited applications of these techniques on the Magnetom Terra Siemens 7T system (FDA approved for brain imaging in [ADDRESS_40048] Research Institute for The University of [LOCATION_007] MD Anderson Cancer Center faculty usage) and 
specifically related to brain cancer. This study seeks to validate these techniques on this specific system in a population of patients with known or suspected brain cancer. 
The majority of all malignancies of the central nervous system can be categorized as either 
primary brain neoplasms (such as primary brain tumors ) and metastatic disease (such as from 
breast cancer, lung cancer or melanoma).  There has been  growing recognition of the need  for 
novel, effective therapi[INVESTIGATOR_38139] . Vice President  Joseph Biden  in a January 15, 
2016 roundtable at  the Abramson Cancer  Center  stated  a goal of catalyzing  greater  investment,  
coordination, and  collaboration  in cancer  therapy  including a specific focus on advances  in the 
Proprietary Information of MD Anderson
Protocol No: 2019-1032 
Version No: 10 
Version Date:  August 25, 2023 
8 
 treatment  of glioblastoma.  Currently  validated  treatments  for glioblastoma  and other central  
nervous system  tumors are  few in number and  short  on proven effectiveness.  These treatments  
are also  often  toxic, threaten  neurological function, and  hamper  the quality  of remaining  life. The 
Brain  Tumor Center  at the MD Anderson has  defined  their  Glioblastoma  Moon Shot goal as  an 
aim for better,  safer  therapeutics  along with  quadrupling the five -year survival rate,  from  10% to  
40% over the next  decade.  [1] 
Despi[INVESTIGATOR_38140], there are limited  
advanced  MR features  that have enough validated  evidence to  support clinical  implementation  to 
assist  in evaluating  tumor response. Techniques including diffusion- weighted  imaging  (DWI),  
diffusion tensor imaging, perfusion MRI,  and magnetic  resonance spectroscopy (MRS) allow  
tumor assessment  at the metabolic  and physiologic level,  but they  have not yet  been  able to  
reliably  identify  tumor volumes or differentiate  tumo r recurrence from  pseudoprogression and  
radiation  necrosis. [2] [3]  [4] [5] [6] A significant challenge in  the field  of MRI  has been  the 
ability  to meaningfully compare findings across  studies and  institutions  due to  wide  variability  in 
the image  acquisition, post-processing, analysis,  and interpretation.  
Ultra -high field  (U HF) MRI  shows promise to  improve detection  and characterization  of brain  
tumors, preoperative planning for neurosurgical resection,  and longitudinal monitoring of the 
effects  of radiation  and antibody- based  therapi[INVESTIGATOR_014].  Addition research  revealed  that the clinical  
advantages  of 7T magnets,  including higher signal- to-noise ratio,  higher contrast -to-noise ratio,  
smaller  voxels, and  stronger susceptibility  contrast,  may  increase lesion  conspi[INVESTIGATOR_3934], detection  
and characterization  compared  to lower  field  1.5T and 3T. [7] 
2.[ADDRESS_40049] aggressive form  of 
primary brain tumor, glioblastoma,  in clinical  trial populations is  16 months . There has  been  an 
unfortunate stagnation in  the ability  of non-invasive diagnostics to  accurately  differentiate  
between  treatment  response and  failure.  Even  under optimal circumstances  with  the use of ‘state  
of the art'  diagnostic and  therapeutic interventions, less  than  15% of patients  will survive five  
years.  [8] [9] [10] While  the introduction of temozolomide  into the first -line standard  of care [11] 
achieved  some survival improvement, nearly  all patients  relapse and treatment  options for 
recurrent  disease remain  limited  and largely  ineffective.   
The a bility  to measure the  response to  treatment  is a critical  component in  evaluating the efficacy  
of new  therapi[INVESTIGATOR_014].  Unfortunately, current  diagnostic neuroimaging paradigms fail  to evaluate 
treatment  response for glioblastoma reliably.  The initial landmark  imaging  evaluation  guidelines 
– the Macdonald  criteria  – were established  in [ADDRESS_40050]  agent  across  a disrupted blood-brain: changes  in 
contrast -enhancement  may  be attributable  to real progression, imaging  technique, treatment  
(surgery,  radiation, or chemotherapy),  steroids and  parenchymal  changes  unrelated  to the tumor 
(postsurgical changes,  ischemia,  seizures).  Particularly  with  the use of multimodal therapy  with  
radiation  and temozolomide and  new  systemic  therapi[INVESTIGATOR_38141],  new  radiological 
Proprietary Information of MD Anderson
Protocol No: 2019-1032 
Version No: 10 
Version Date:  August 25, [ADDRESS_40051] associated  toxicities.  Moreover, such  misclassification  may  
confound the data obtained in  such  studies and  may  lead  to false conclusions with  regards  to the 
efficacy  (or safety)  of an  investigated  drug. An  effort  to address  this challenge to  accurately  
evaluate brain  tumor response resulted  in the formation  of the Response Assessment  in Neuro -
Oncology (RANO)  working group. In  2010, this  group published updated guidelines for 
response assessment  of high-grade gliomas  incorporating additional MRI  and clinical  
considerations, which  addressed  the recognized  and accepted  limitations  of the Macdonald  
Criteria.  [12] 
Advanced  imaging  techniques that  provide added  value in  the evaluation  of primary brain tumors 
include MRS  for detection  of a 2- HG peak  which  identifies  patients  at harboring an  IDH1/[ADDRESS_40052]  
2HG in  addition to  other neuro metabolites  was demonstrated. [13] 7T MRS  has also provided a 
better  detection  of major  neuronal metabolites  when  there are overlappi[INVESTIGATOR_38142].  This  is a feat  
that is often  challenging with technology at  3T and  1.5T imaging  systems.  [14] 
2.[ADDRESS_40053] been reported to occur in up to 30% of patients with cancer, and treatment 
options include supportive care, surgery, and radiotherapy. [15]  The incidence of brain 
metastases is increasing, partly because of increase in the incidence of primary cancers and partly because improvements in treatment options have prolonged survival of patients with cancer, which increases the chance of primary tumo rs metastasizing. [16] There are very few 
chemotherapy options open to patients with brain metastases.  Stereotactic radiosurgery (SRS) has become an increasingly important treatment option for the initial management of patients with brain metastases. Early and accurate detection of small metastases is associated with improved treatment success. [17]  At present, gadolinium-enhanced MRI is considered to be the 
imaging technique of choice in patients suspected of brain metastases . [18]  
Significant limitations to the utilization of gadolinium-enhanced MRI in the screening for brain metastasis is cost and the requirement of an intravenous injection of a contrast agent. [19] Some patients have claustrophobia requiring sedation. Additionally, underlying conditions, such as back pain , may make it hard for the patients  to lie still for the  duration of the MRI . Achieving 
standard -of-care MR imaging in these populations can be challenging. There is a vital clinical 
necessity for a safe and efficient screening imaging technology to offer patients as risk of brain metastases, who have contraindications to gadolinium as well as the ability to tolerate long examination times . [20] 
A comparison of brain malignancy at 7T and 3T revealed that routine contrast doses at 7T provided higher lesion enhancement than the full dose at 3T, which indicates the possibility of 
Proprietary Information of MD Anderson
Protocol No: 2019-1032 
Version No: 10 
Version Date:  August 25, [ADDRESS_40054] dose reduction at 7T. This could provide particularly useful in pediatric and renal failure 
populations. (Noebauer-Huhmann, 2015)  
This UHF work on patients with multiple sclerosis at 7T revealed the ability of the combination 
of MP2RAGE (magnetization prepared 2 rapid acquisition gradient echoes) and T2*-weighted imaging at 7T to improve detection of cortical lesions. This work suggests that similar techniques could be used to improve detection of small metastases, including those involving the cortical structures . [21] 
2.3 Quantitative MRI  
 Intensity values on routine MR imaging are not defined in terms of any consistent scale since the signal is dependent on many hardware and patient- specific factors. Hence there is very little 
gained in measuring the “bright” or “dark” pi[INVESTIGATOR_38143], and the images must be 
interpreted subjectively. [22] This would be analogous to subjectively describing “hot” or “cold” spots on an infrared heat map image when the absolute temperature scale of the pi[INVESTIGATOR_38144]. This study proposes to use multi-parameter mappi[INVESTIGATOR_38145]. In MR imaging, hydrogen nuclei or "spi[INVESTIGATOR_2115]" are the sources of the signal. In the strong magnetic field of an MR scann er, these spi[INVESTIGATOR_38146]. Thus, contrast mechanisms in MR imaging are highly dependent on the hydrogen spin density or proton density (PD), as well as the longitudinal and transverse relaxation times (T1 and T2, respectively), which tend to vary between different tissues or fluids. However, measurement of relaxation times requires multiple acquisitions, and as a result, measurement or quantitation of these parameters can be excessively long for clinical MR exam.    Recent developments in rapid multi-parameter mappi[INVESTIGATOR_38147]. [22, 23] These typi[INVESTIGATOR_38148]. SyntheticMR developed the first clinically available method and released by [CONTACT_38168] "MAGIC" (MAGnetic resonance Image Compi[INVESTIGATOR_344]), which can achieve whole-brain quantitation in 5-6 minutes. [24] The SyntheticMR method assumes the process of T1 and T2 relaxation times to be monoexponential, whereas it may be multi-exponential for many tissues. However, a phantom study has revealed good accuracy and reproducibility for T1, T2, and PD measurements by [CONTACT_38169]. These measured parameters can also be applied to an MR spin model produce images with almost any contrast weighting by [CONTACT_38170] (TR), echo time (TE), and inversion time (TI). [ADDRESS_40055] settings (for example, T1 weighted imaging (WI), T2WI, proton density WI) are required. Synthetic MRI of the brain without the use of a contrast agent has been reported to produce images that although inferior in image quality the diagnostic power of the images was comparable to that of images obtained via conventional MRI sequences. [25] Therefore, if the diagnostic power of images obtained via synthetic MRI after 
administration of a contrast agent is also proved to be comparable to that of conventional MRI, synthetic MRI could be a useful means of screening for brain metastases , significantly reducing 
scan time and providing quantitative data. [26]  
Proprietary Information of MD Anderson
Protocol No: 2019-1032 
Version No: 10 
Version Date:  August 25, [ADDRESS_40056] imaging at UHF. These results indicate the 
potential utility of amide proton transfer ( APT ) at the high field as a noninvasive biomarker of 
white matter pathology, providing complementary information to other MRI methods in current clinical use. Also, contrary to results obtained at lower fields, APT imaging at 7T revealed significant contrast b etween white and gray matters, with a higher APT signal apparent within 
the white matter. These findings suggest that UHF CEST imaging would be sensitive to alternations in the APT signal related to both malignancies and treatment- related changes. [27] 
 
2.4 Multiple B -Value Diffusion Imaging (Adv Diff) 
 
Molecular diffusion is a stochastic process, and, as such, it may be described by [CONTACT_38171]. The most basic of these is the probability of a molecule moving a given displacement over a given time interval. For pure, homogeneous liquids (e.g., a glass of water), this displacement probability distribution function is Gaussian, and the diffusion is referred to as Gaussian diffusion. In conventional MR imaging, diffusion of water molecules in the tissues has a tiny contribution to the MR signal. In diffusion MRI, powerful magnetic gradients with an echo -planar sequence are used. Thus, the measurement of the molecular diffusion of water has 
been possible for decades using MRI, and diffusion-weighted imaging (DWI) with MRI has been possible for greater than thirty years. [28]  
 A diffusion coefficient called apparent diffusion coefficient (ADC) value can be calculated within each image voxel, and ADC maps can be generated on a pi[INVESTIGATOR_8070] -by-pi[INVESTIGATOR_38149]. Because 
diffusion coefficients are high in fluids where diffusion is free, a low signal is observed on diffusion imaging at b = 1000 mm2/s (high signal on corresponding ADC maps). Normal CSF is an example of this. On the other hand, if the mobility of water molecules is restricted such as in ischemia (cytotoxic edema) high signal is observed on diffusion imaging at b = 1000 mm2/s (low signal on corresponding ADC maps). [29]  Diffusion -weighted imaging has been proposed as a set of tools to improve diagnostic accuracy 
a
nd achieve a better understanding of the pathophysiology of brain cancer. A specialized form of 
DWI is diffusion tensor imaging (DTI) that provides information not only about the random displacement, or passive diffusion, of water molecules but also about fiber directionality and 
integrity . DTI can allow visualization of neuronal projections in the central nervous system and 
estimation of the neuronal changes in the white matter of healthy subjects and patients with various neurological diseases. [30]  Fractional anisotropy (FA) and mean diffusivity (MD) obtained from diffusion tensor imaging (D
TI) has been used to assess the nature of brain metastasis and their response to treatment. 
However, FA and MD have limitations in accurately evaluating brain metastasis . New 
technologies, such as diffusion kurtosis imaging (DKI), can provide a more informative insight into the biology of tissue, including brain metastasis. [31] An advantage of DKI is that it is relatively simple to implement for human imaging on conventional MRI clinical scanners. DKI protocols differ from DTI protocols in requiring at least three b-values (as compared to 2 b-values for DTI) and at least 15 independent diffusion gradient directions (as compared to 6 for DTI). Typi[INVESTIGATOR_38150] b-values of 0, 1000, 2000 s/mm2 with 30 diffusion 
Proprietary Information of MD Anderson
Protocol No: 2019-1032 
Version No: 10 
Version Date:  August 25, 2023 
12 
 directions. The apparent excess kurtosis coefficient  (AKC) is a dimensionless metric that 
quantifies the degree of deviation from Gaussian diffusion behavior. [32]  
 Defining the relationship between DKI and brain metastasis prior, during and following treatment can provide more abundant imaging to guide cancer diagnosis and treatment. [33] DKI has been used to measure the non- Gaussian nature of water diffusion, which can reveal a more 
complex microstructure in both normal and pathological tissues compared to DTI alone. Previous studies have demonstrated that there was a significant difference in mean kurtosis (MK) value between high- and low -grade astrocytomas. [34] However, to the best of our knowledge, 
no comparison of different diffusion imaging approaches for assessing brain metastasis has been performed.  
 Early work on DKI at UHF suggests that it is not only feasible but provides improvements over diffusion imaging at lower field strengths. Researchers have shown that with modern statistical approaches, including an autoregressive model for the inference that ultra -high field functional 
magnetic resonance imaging is successful.  [35] Additional research has shown that UHF DKI is 
a viable option for imaging tissue change in MS lesions and normal-appearing WM. [36]  
2.5 Chemical Exchange Saturation Transfer (CEST) MRI  
 
Chemical exchange saturation transfer (CEST) is a promising new MRI contrast mechanism that has been used in studying the tumor microenvironment through the detection of mobile proteins and peptides. This technique relies on the labeling of endogenous populations of exchanging protons by a radiofrequency pulse at a specific frequency. These pools can transfer their magnetization to the unbound water (through the exchange), the extent of which constitutes the MRI image contrast, and by [CONTACT_38172], a spectrum is generated. In the absence of the CEST effect, this spectrum is generally considered to be 
symmetric; however, in its presence, the signal is attenuated at specific frequencies, resulting in chemical -specific negative peaks.  Two CEST effects apparent in vivo are attributed to protons of 
mobile proteins: backbone amide signals with their base-catalyzed proton transfer (APT), and nuclear Overhauser enhancement (NOE) mediated aliphatic proton magnetization transfer (so -
called exchange- relayed NOE. [45]  
 MRI based on the chemical exchange saturation transfer (CEST) effect from amine, amide, sulfhydryl, and hydroxyl protons associated with endogenous metabolites has been shown to provide imaging maps of metabolites in tissue noninvasively. [46] Amide proton transfer (APT) imaging has been developed, which detects amide protons of low concentration in endogenous proteins and peptides in tissue. [47] APT has shown promising results in differentiating radiation necrosis from tumor progression in primary brain tumors and necrosis models in rats. [48] APT has also been applied to human primary brain tumor patients to differentiate high -grade tumors 
from low -grade ones with encouraging results. [49] 
 Ten glioblastoma patients were studied in this paper which revealed  both that CEST imaging was 
feasible at 7T and also that it appeared to provide superior information to CEST imaging performed at lower field strengths (including 3T). Signal and contrast gained in CEST imaging at 
Proprietary Information of MD Anderson
Protocol No: 2019-1032 
Version No: 10 
Version Date:  August 25, [ADDRESS_40057] changes in tumors and correlations on a cellular and molecular level.  [45] 
 
2.6 Multiple inversion time (TI) arterial spin labeling  (ASL) “Adv ASL” perfusion 
imaging 
 
Arterial spin labeling (ASL) is an MRI technique that can noninvasively and quantitatively  
determine  cerebral blood flow ( CBF ) by [CONTACT_38173][INVESTIGATOR_38151]. [50] This method takes advantage of the fact that water protons of the 
arterial blood in the feeding vasculature of the brain are magnetically labeled and used as an endogenous tracer. After a specific inversion time, the labeled blood arrives at the image plane in which the image is acquired.  In clinical studies, it has been used to assess perfusion in 
neurodegenerative diseases, epi[INVESTIGATOR_002], central nervous system neoplasms, and vascular malformations. [51] However, a disadvantage of ASL- MRI is that in patients with 
cerebrovascular disease, the quantification of CBF is hampered by [CONTACT_38174]. [52] These alternative pathways of blood flow lead to delayed arrival of the labeled blood bolus to the brain. [53]   As most ASL -MRI techniques acquire the labeled images at a fixed time after the initial labeling 
of arterial blood, it is possible that the magnetic label may not have reached the imaging plane, leading to underestimation of CBF. Previous studies reported that tumor-brain blood flow ratios determined by [CONTACT_38175] -labeling were markedly higher than those obtained with dynamic 
susceptibility -weighted contrast-enhanced MR imaging. [54] The underestimation of perfusion 
probably causes this in brain regions with long arterial transit times. The use of higher inversion times would overcome these limitations; however, this would conversely lead to a decrease in the SNR caused by [CONTACT_38176]. Recently, ASL -MRI 
with the acquisition of a series of images at multiple delay times after the initial labeling has been introduced as a method to compensate for these issues and also demonstrated the ability to differentiate low -grade and high- grade astrocytomas . [55] 
 The inherently low contrast- to-noise ratio of ASL techniques is substantially improved when 
scanning at 7T, which allows data to be collected at higher spatial resolution. This work demonstrated the ability to quantify the perfusion of small cortical lesio ns in MS at 7 Tesla, 
demonstrating that an optimized ASL acquisition is sensitive to focal hemodynamic pathology. [56]  
2.7 Protocol Particular Disease Description  
 
Brain malignancy  will be defined as suspected or pathologically proven space-occupying intra-
axial lesion. Suspected (not pathologically proven) brain malignancy will require confirmed suspi[INVESTIGATOR_38152] a neurosurgery and neuroradiology collaborator.  
Proprietary Information of MD Anderson
Protocol No: 2019-1032 
Version No: 10 
Version Date:  August 25, 2023 
14 
 3 ELIGIBILITY  
3.1 Inclusion Criteria  
 
Patients  
• 13 years old and above. 
• Written Informed consent must be obtained by [CONTACT_102] (age 13-17)’s parent or legally 
authorized representative (LAR)  
• Patients must meet one set of inclusion criteria:  
o Newly identified and untreated primary brain tumor or metastasis of at least 5 mm 
or greater in size.  
 Suspected central nervous system neoplasms will require agreement from a study neuroradiologist and a study neurosurgeon, neuro-oncologist, or a radiation oncology that a lesion exists that is most likely either a primary brain tumor or a metastasis.  
 Patients with suspected brain metastasis must also have a history of solid organ malignancy . 
o History of primary brain tumor or metastasis treated with surgery, radiation, chemotherapy, or immunotherapy with new or increasing signal on MR imaging that is suspi[INVESTIGATOR_38153] (treatment failure). 
 Suspected recurrent neoplasms will require agreement from a study neuroradiologist and a study neurosurgeon, radiation oncologist, or neuro-oncologist that lesion behavior is suspi[INVESTIGATOR_38154]. 
Healthy Volunteers 
• Volunteers without history of brain cancer. 
• 13 years old and above. 
• No pregnant subjects will be enrolled. 
• No contraindications to MR exam(s) – healthy volunteers will use the same screening process utilized for MDACC patients. 
• Written Informed consent must be obtained by [CONTACT_102] (age 1 3-17)’s parent or legally 
authorized representative (LAR)  
 
3.2 Exclusion Criteria  
 Patients  
• Contraindication to MR imaging. 
• Absolute or relative contra-indication to 3T MRI due to metallic foreign bodies and devices and/or other conditions that are not MR safe, which include implants with unknown behavior in 3T MRI as well as: 
o electronically, magnetically, and mechanically activated implants  
o ferromagnetic or electronically operated active devices like automatic cardioverter 
defibrillators and cardiac pacemakers  
o metallic splinters in the eye  
o ferromagnetic hemostatic clips in the central nervous system (CNS) or body 
o cochlear implants  
Proprietary Information of MD Anderson
Protocol No: 2019-1032 
Version No: 10 
Version Date:  August 25, 2023 
15 
 o other pacemakers, e.g., for the carotid sinus 
o insulin pumps and nerve stimulators 
o non-MR safe lead wires  
o prosthetic heart valves (if dehiscence is suspected)  
o non-ferromagnetic stapedial implants  
• pregnancy 
• Claustrophobia that does not readily respond to oral medication 
• Known allergy to gadolinium- based contrast agents.  
• Renal failure as defined by a GFR less than 30 or the use of hemodialysis. 
• Pregnant. 
• Patients less than 13 years of age will be excluded.  
• Interval treatment with radiation or surgery between the diagnostic MRI lesion 
identification and planned study MRI. 
• Wards of the state  
 
3.3 NUMBER OF PARTICIPANTS  
 
One hundred (100) patients will be studied.  Up to twenty (20) healthy volunteers will be studied 
for the purposes of MRI sequence optimization.   
4 STUDY PLAN/DESIGN 
4.1 Patient Enrollment:  
 
Patients  being evaluated  for treatment  of a suspected  brain  malignancy  at MD Anderson Cancer  
Center  will be screened  for eligibility  based  on their  screening  diagnostic MRI  scan  and available  
clinical  information.  Once eligibility  is confirmed, patients  will be approached for protocol 
introduction and  consenting and  enrollment.  Attempts  will be made to  scan  patients  in the 7T 
system  within  30 days of an  MRI  scan  performed  at either  3T or 1.5T.   
 Up to twenty  (20) healthy volunteers will be recruited  through local  advertisement  for the 
purposes of MRI  sequence optimization.  Volunteers will be scanned  in accordance with  the 
UTMDACC  Division  of Diagnostic Imaging Policy  # 3.00: Imaging of Healthy  Volunteers for 
Quality  Assurance/Improvement and  Technical  Development. 
 
4.2 Procedure to Obtain Consent  
 
Th
e patients and volunteers will be approached  in person or using IRB approved remote consent 
procedures by [CONTACT_38177] (DI) faculty or Research Staff, including research 
nurses and research coordinators for their approval before their procedure. For subjects’ age [ADDRESS_40058]’s entry into the study and prior to any study related procedures.  During the consenting process, patients will be educated and consented for their 
Proprietary Information of MD Anderson
Protocol No: 2019-1032 
Version No: 10 
Version Date:  August 25, [ADDRESS_40059] Research Institute (HMRI) Registration 
 
If inclusion/exclusion criteria are met and patients agree to participate in the study, the research study team will then contact [CONTACT_38178] (HMRI) to register the patient and schedule their research MRI scan. Patient information including patient name, date of birth, prior allergic reaction to gadolinium based contrast agents, prior surgical history (as it pertains to surgical implants which may be a contraindication to MR scanning) which will be provided to HMRI as part of the study procedure (A ppendix A – MRI Safety Questionnaire) and 
Referral Questionnaire for MDACC (Appendix B).     A copy of the completed MRI safety questionnaire and Referral Questionnaire for MDACC will 
be stored in RED Cap and only authorized  members of research team  from MD  Anderson (MDA) 
& HMRI  who signed the delegation of authority log will have access to the data.  
 Research patients  and volunteers will be contact[CONTACT_38179].     
4.4 MR Scanning:  
 
Patients:  
 
The study MRI  will be performed  on a 7.0-T MRI  system.  All patients  will undergo 
conventional anatomic  MR imaging  including 3D T1 pre and post- contrast  weighted  
imaging , 3D T2  weighted imaging, 3D T1  SPACE  post- contrast,  dynamic contrast -enhanced  
perfusion imaging, magnetic  resonance spectroscopic imaging, functional magnetic  
resonance imaging  (speech  and motor paradigm), as well  as the study- specific  sequences  to 
include:  
• Quantitative MRI  
• CEST 
• Adv Diff  
 
• Adv ASL  
 The entire  scan  time  is expected  to be approximately sixty  (60) minutes.  Routine and  study 
sequences  obtained on the  7T system  may  be obtained with  the system  in parallel  transmit 
(pTx) scanning mode. Scanning in  pTx mode can  lead to increases  in specific absorption rate 
(SAR) compared  to single transmit mode; however, system  software  controls and  sequences  
in both modes adheres  to non-significant risk  standards  as defined by [CONTACT_38180] [ZIP_CODE] and the 
Proprietary Information of MD Anderson
Protocol No: 2019-1032 
Version No: 10 
Version Date:  August 25, 2023 
17 
 US Food & Drug  Administration  including specifically  that the SAR  for the head  will be less  
than 3.2W/kg head . 
 
Volunteers: 
  
The study MRI  will be performed  on a 7.0-T MRI  system.  Volunteers will not get an IV line 
placed or receive contrast  as per UTMDACC Division of Diagnostic Imaging Policy # 3.00: 
Imaging of Healthy Volunteers for Quality Assurance/Improvement and Technical Development.   Volunteers will undergo a selection  of research  sequences  above for  the purposes of 
sequence optimization  and quality  assurance.  The volunteer scan  time  is expected  to be 
approximately sixty  (60) minutes.  Routine and  study  sequences  obtained on  the 7T system  
may be obtained with  the system  in parallel  transmit (pTx) scanning mode. Scanning in  pTx 
mode can  lead  to increases  in specific absorption rate (SAR) compared  to single transmit 
mode; however, system  software  controls and  sequences  in both modes adheres  to non-
significant risk  standards as  defined  by [CONTACT_38180] [ZIP_CODE] and  the US  Food & Drug  
Administration  including specifically  that the SAR  for the head  will be less  than  3.2W/kg 
head . 
 
4.5 Patient  experience survey  
Patients will be given a one-page survey regarding their experience in the 7T MRI system 
following their scan. For subjects’ age [ADDRESS_40060]’s parent or LAR to complete any missing responses.
 
4.5.1 [Appendix A] 
 
4.[ADDRESS_40061] of care.  These follow-
up scans will serve as the basis for statistical analyses that consider treatment response or 
disease recurrence.  
 
4.7 C
onclusion of Study Participation: 
4.7.[ADDRESS_40062].  
4.7.3 Death.  
 
Proprietary Information of MD Anderson
Protocol No: 2019-1032 
Version No: 10 
Version Date:  August 25, 2023 
18 
 5 Image Analysis 
5.1 Lesion  size evaluation: 
5.1.[ADDRESS_40063] diameter after appropriate 
magnification on the pi[INVESTIGATOR_38134] (PACS) monitors.  
5.1.3 For patients with multiple  lesions appropriate for study assessment, the five  (5) largest 
lesions will be assessed . 
 
5.2 Lesion  CNR evaluation: 
5.2.[ADDRESS_40064] imaging will 
be placed and will define the lesion ROI. 
5.2.2 The ROI  mean  signal intensity will be recorded. 
5.2.3 A mirror ROI will be placed in the contralateral normal-appearing white matter and used 
as the "background" mean signal intensity measurement.  
5.2.[ADDRESS_40065] will be used as the “noise” mean signal 
intensity measurement.  
 
5.[ADDRESS_40066] imaging will 
be placed  and will define the lesion ROI. 
5.3.2 The T1 and T2 tissue weighting that maximizes the ROI mean signal intensity will be 
identified.  
5.3.3 A mirror ROI will be placed in the contralateral normal-appearing white matter and used 
as the "background" mean signal intensity measurement.  
5.3.[ADDRESS_40067] will be used as the mean “noise” signal intensity measurement.  
 
Proprietary Information of MD Anderson
Protocol No: 2019-1032 
Version No: 10 
Version Date:  August 25, [ADDRESS_40068] data will be used as the “background” mean signal intensity 
measurement.  
5.4.[ADDRESS_40069] will be used as the “noise”  mean  signal 
intensity measurement.  
 
5.5 Multiple B Value Diffusion Imaging (Adv Diff)  
5.5.[ADDRESS_40070] imaging will 
be placed and will define the lesion ROI. 
5.5.2 The AKC for the lesion will be determined using B-values of 0, 1000, and 2000 mm2/s.  
5.5.3 The ADC of the lesion will also be determined  using B-values of 0 and 1000 mm2/s. 
5.5.4 A mirror ROI will be placed in the contralateral normal-appearing white matter, and 
"background" AKC and ADC measurement will be measured . 
 
5.[ADDRESS_40071] imaging will 
be placed and will define the lesion ROI. 
5.6.2 This ROI will be used to assess the cerebral blood flow (CBF) from the processed ASL 
data. 
5.6.3 A mirror ROI will be placed in the contralateral normal-appearing white matter for 
assessment of the “background” CBF.  
5.6.4 This ROI will be used to assess the bolus arrival time (BAT) from the processed ASL data.  
 
Proprietary Information of MD Anderson
Protocol No: 2019-1032 
Version No: 10 
Version Date:  August 25, 2023 
20 
 5.7 Task- based fMRI  
5.7.1 fMRI data will be analyzed using custom software, IClinfM RI.  
5.7.2 The general linear model  will be  used to generate an activation t -value map for each task -
based  fMRI data.  The model includes the convolution of the task paradigms with a 
canonical hemodynamic response function. 
5.7.3 Significantly activated areas  will be  determined by [CONTACT_38163] t- value map at 
corrected P  < .05. 
 
5.8 Resting -state fMRI  
5.8.1 Resting -state datasets  will be  pre-processed through slice timing, motion correction, de-
spi[INVESTIGATOR_28884], detrending, regressing out covariates (including six motion parameters and two 
averaged fluctuations over masks of white matter and cerebrospi[INVESTIGATOR_872]), band- pass 
filtering of 0.01-0.[ADDRESS_40072] and distortion.  
5.9.3 The geometric distortion will be evaluated with a full-field geometric distortion phantom 
to assess the geometric accuracy of the SPACE sequence with its specific parameters.  
5.9.4 For radiation therapy purposes, the geometric distortion of less than 1mm is desired for 
the typi[INVESTIGATOR_38135] 2 mm is the targeted limit for the useable field of view 
 
Proprietary Information of MD Anderson
Protocol No: 2019-1032 
Version No: 10 
Version Date:  August 25, 2023 
21 
 6 Patient Information Confidentiality Plan 
6.1 Collection of Identifiers:   
The patient identifiers that will be collected in this study consist of patient medical record numbers 
and dates. Electronic data will be kept securely at MD Anderson (password protected behind the institution firewall).  
 The study will be performed following institutional policies for the use of existing medical information for research. Confidentiality will be maintained throughout the study. No identifying information will be used in any publication from this study. Elec tronic study data will be stored 
on password- protected institution computers behind the institution firewall. Only the PI [INVESTIGATOR_38155] (HSPT) will have access to the study data. 
 
6.2 Training of personnel:  
Only MDACC personnel designated by [CONTACT_978] [INVESTIGATOR_38156].  These personnel will be fully trained to maintain patient health information confidentiality. 
 
6.3 Data Storage: 
Electronic study data will be kept on password-protected computers behind the institution firewall.  Paper records (data forms, and unique identifiers, etc.) will be kept in a locked file cabinet with access granted only to study investigators and research staff.  
 
6.4 Data Sharing: 
Study will utilize  REDCap to store and share data with study collaborators and research staff 
with HMRI .  Only authorized members of research team  from MDA & HMRI who  signed the 
delegation of authority log will have access to the data in REDCap.  Study data will be collected and managed using the REDCap (Research Electronic Data Capture) system  hosted at MD Anderson. REDCap (www.project- redcap.org) is a secure, web -based 
application with controlled access designed to support data capture for research studies, providing: 1) an intuitive interface for validated data entry; 2) audit trails for trac king data 
manipulation and export procedures; 3) automated export procedures for seamless downloads to common statistical packages; and 4) procedures for importing data from external sources. REDCap (https://redcap.mdanderson.org) is hosted on a secure server by [CONTACT_38181]'s Department of Oncology Care & Research Information Systems. REDCap has undergone an annual Governance Risk & Compliance Assessment (since May 2014) by [CONTACT_38182]'s Information Security Office and found to be compliant with HIPAA, [LOCATION_007] Administrative Codes 202-203, University of [LOCATION_007] Policy 165, federal regulations outlined in 21CFR Part 11, and UTMDACC Institutional Policy #ADM0335.  Those having access to the data include the study PI [INVESTIGATOR_38157] & HMRI . Internal users are authenticated against MDACC's Active Directory system. External 
Proprietary Information of MD Anderson
Protocol No: 2019-1032 
Version No: 10 
Version Date:  August 25, 2023 
22 
 users will be granted access to the study.  The application is accessed through Secure Socket 
Layer (SSL). The linking of patient protected health information (PHI) will be removed from the data when it is exported from REDCap for final analysis. All dates for a given subject will be shifted by a randomly generated number between [ADDRESS_40073]. Max Wintermark , Principal Investigator [INVESTIGATOR_38158]: 2019-1032. Complete confidentiality will be maintained; the investigators will be responsible for the transmission, sharing and storage of research imaging data.  
 
6.5 Final Disposition of study records: 
After publication, any printed paper records will be placed into the Shred- it confidential waste bins 
for disposition. The study will be performed following current institutional standards for the use 
of existing medical information, banking the data, and identifiers for research. There will be no further use of the study data without prior review and approval by [CONTACT_1201].  
7 STATISTICAL CONSIDERATIONS   
7.1 Definitions  
7.1.1 Lesion  “treatment response” will be defined by [CONTACT_38164] ( CNR ).  
Treatment response will be assessed only in patients with treatment  prior to enrollment.  
[IP_ADDRESS] Size – treatment response in a single lesion will be considered as a decrease in size of 
30%. (see section 5.1) 
[IP_ADDRESS] CNR —treatment response will be considered as a decrease in T1 post-contrast CNR of 
at least 20%. (see section 5.2) by [CONTACT_38183] T1 post-contrast imaging.  
[IP_ADDRESS] Lesions that do not meet these criteria for treatment response will be considered treatment failure.  
7.1.2 Disease recurrence will be determined by [CONTACT_38165] (if available) or at least three months of imaging follow-up.  Disease recurrence will be assessed only in patients with treatment prior to enrollment. Imaging findings will be considered recurrent disease in a lesion if: 
[IP_ADDRESS] The lesion was  initially considered to be a treatment responder.  
[IP_ADDRESS] The lesion showed a successive increase in the size of 25% from nadir or a single imaging time point increase of 40%. (see section 5.1) 
[IP_ADDRESS] Lesions that do not meet these criteria will be considered radiation necrosis. 
 
Proprietary Information of MD Anderson
Protocol No: 2019-1032 
Version No: 10 
Version Date:  August 25, 2023 
23 
 7.2 Overview  
 
Patients with untreated disease (new lesions) will be categorized as having brain metastasis, primary brain tumor, or non-tumor based upon the following:  
1. Patients with well-defined intra-axial lesions seen in the setting of pathology-proven solid organ malignancy will be considered metastasis. 
2. Patients with out history of a primary malignancy and agreement on a likely diagnosis of 
primary brain tumor by [CONTACT_17588] a neurosurgical and neuroradiology co-investigator will be considered primary brain tumor. 
3. Patients that do not the above criteria will be categorized as having non-tumor. 
 Patients in categories 1 and 2 will be further classified as having received treatment and not having received treatment.  
    
7.3 Sample Size 
 
The healthy volunteer s’ data will only be used for fMRI sequence optimization, quality 
assurance and will not yield data for the study.  The optimization scans on healthy volunteers will not affect the statistical results . 
 Patients will be divided into 5 groups as discussed above.  It is assumed that 90% of patients enrolled will represent either brain metastasis or primary brain tumor, approximately half in each category . We also expect approximately half of each group to have received treatment.  We thus 
expect to have approximately 20-[ADDRESS_40074] four groups (metastasis with and without treatment and primary brain tumor with and without treatment) .  The other 10% will be 
in group 5 and are assumed to be non-tumor mimics of malignancy (for example, stroke, demyelinating disease).   
 For the primary endpoints, the objective is to calculate the contrast- to-noise ratio (CNR) or 
equivalent parameter for each method  for both primary brain tumors and metastases  separately 
by [CONTACT_38184] .  For each imaging modality, we will calculate the 
CNR separately in the largest lesion/metastasis per patient as well as in all study lesions (see 5.1.3).  As an example, for CEST, under the a ssumption of only a single lesion per patient and an 
expected mean CEST CNR of 14.[ADDRESS_40075] deviation of 3.0, 20 patients in a 
group will give a 95% confidence interval between 13.6 and 16.2. [40] Similar calculations apply for the CNR for each of the other imaging modalities.  
 We may also combine groups for the purpose of analysis.  Continuing the above example, w ith 
[ADDRESS_40076] deviation, a 95% confidence interval around the CEST CNR will range from 14.0 to 15.8.  Again, similar calculations apply for other imaging modalities. 
Proprietary Information of MD Anderson
Protocol No: 2019-1032 
Version No: 10 
Version Date:  August 25, [ADDRESS_40077] lesion within patients, and some analyses will be repeated on a per-lesion basis.   The CNR for each imaging method will be determined and reported along with the corresponding 95% confidence interval.  In secondary analyses, for the conspi[INVESTIGATOR_38159], the T1 sequence by [CONTACT_38185], and we will compare the conspi[INVESTIGATOR_38160] T1 sequencing by [CONTACT_38186]’s test.  This analysis will first be performed in the lar gest lesion per patient, and then analyses will be 
repeated using all lesions.  If enough follow-up images are obtained (see section 4.5) , we will compare the CNR in lesions 
that respond to treatment to those that do not by [CONTACT_2329] a Wilcoxon rank- sum test.  We will 
compare the CNR between baseline and follow-up within patient by [CONTACT_2329] a Wilcoxon signed-rank test.  Also, for those lesions that initially respond, some will subsequently grow in size after the initial response.  Of these, some will be considered radiation necrosis and some progressive disease.  The CNR will be compared betw een lesions with necrosis and those that are progressive 
disease using a Wilcoxon rank- sum test.  
 Exploratory aims will be analyzed with descriptive statistics. fMRI paradigms will be summarized by [CONTACT_38187].  P atient satisfaction will be reported on a 
five-point Likert scale and  compared between the 7T scan and the most recent clinical scan  by 
[CONTACT_2329] a Wilcoxon rank- sum test.  
 
[ADDRESS_40078] Research Institute for the Protection of Human Subjects. Participants will be protected according to the processes outlined by [CONTACT_30028].  
 Personal information will be protected by [CONTACT_38188]:  
Proprietary Information of MD Anderson
Protocol No: 2019-1032 
Version No: 10 
Version Date:  August 25, 2023 
25 
 • All HIPAA identifiers including names and medical records will be kept in a confidential 
manner, stored behind the institutional firewall.  Paper copy will be stored in locked file in the office of a study investigators and authorized research staff.    
• Data will be shared with HMRI investigators and staff and only as required to fulfill this research goals and objectives .  
• Study data will be stored into REDCap. Access will be granted to HMRI and MDA study investigators and research staff authorized by [CONTACT_978]. 
• A study code number rather than the participants’ real names will be used on the research 
transcribed documents. This code linking the participants’ demographic information will 
be known only to the study staff and will be kept in a separate locked cabinet in the locked PI’s office at MD Anderson.  
• Study data will be stored permanently on a secure institutional computer behind the institutional firewall in the office of the PI.  
• REDCap will be utilized to store study data, forms, questionnaires and  research MRI 
images .  
• Only  the study investigators and authorized research study staff who signed the 
delegation of authority log will have access to the study data.  
• Study data will be collected and managed using an UT MD Anderson Cancer Center – approved database. The investigators will be responsible for data processing, in accordance with the institution`s data management procedures. 
 
 
9 REFERENCES  
 1. Glioblastoma. In: http://www.cancermoonshots.org/cancer-types glioblastoma. Accessed 
13 Jul 2019 
2. Hamstra DA, Galbán CJ, Meyer CR, et al (2008) Functional diffusion map as an early 
imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. Journal of Clinical Oncology 26:3387–3394. doi: 10.1200/JCO.2007.15.2363 
3. Hu LS, Baxter LC, Pi[INVESTIGATOR_38161], et al (2010) Optimized Preload Leakage-Correction 
Methods to Improve the Diagnostic Accuracy of Dynamic Susceptibility- Weighted 
Contrast-Enhanced Perfusion MR Imaging in Posttreatment Gliomas. AJNR Am J Neuroradiol 31:40–48. doi: 10.3174/ajnr.A1787 
4. Bobek- Billewicz B, Stasik -Pres G, Majchrzak H, Zarudzki L (2010) Differentiation 
between brain tumor recurrence and radiation injury using perfusion, diffusion-weighted imaging and MR spectroscopy. Folia Neuropathol 48:81–92. 
5. Hygino da Cruz LC, Rodriguez I, Domingues RC, et al (2011) Pseudoprogression and 
pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol 32:1978–1985. doi: 10.3174/ajnr.A2397 
Proprietary Information of MD Anderson
Protocol No: 2019-1032 
Version No: 10 
Version Date:  August 25, 2023 
26 
 6. Vöglein J, Tüttenberg J, Weimer M, et al (2011) Treatment monitoring in gliomas: 
comparison of dynamic susceptibility- weighted contrast -enhanced and spectroscopic MRI 
techniques for identifying treatment failure. Invest Radiol 46:390–400. doi: 
10.1097/RLI.0b013e31820e1511 
7. Obusez EC, Lowe M, Oh S-H, et al (2018) 7T MR of intracranial pathology: Preliminary 
observations and comparisons to 3T and 1.5T. NeuroImage 168:459–476. doi: 10.1016/j.neuroimage.2016.11.030 
8. Stupp R, Hegi ME, Mason WP, et al (2009) Effects of radiotherapy with concomitant and 
adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC- NCIC trial. The Lancet 
Oncology 10:459–466. doi: 10.1016/S1470-2045(09)[ZIP_CODE]-7 
9. Ostrom QT, Gittleman H, Liao P, et al (2014) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the [LOCATION_002] in 2007-2011. Neuro-oncology [ADDRESS_40079] 4:iv1–63. doi: 10.1093/neuonc/nou223 
10. Ostrom QT, Gittleman H, Xu J, et al (2016) CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the [LOCATION_002] in 2009-2013. Neuro -oncology 18:v1–v75. doi: 10.1093/neuonc/now207 
11. Stupp R, Mason WP, van den Bent MJ, et al (2005) Radiotherapy plus concomitant and 
adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. doi: 10.1056/NEJMoa043330 
12. van den Bent MJ, Vogelbaum MA, Wen PY, et al (2009) End point assessment in 
gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. Journal of Clinical Oncology 27:2905–2908. doi: 10.1200/JCO.2009.22.4998 
13. Verma G, Mohan S, Nasrallah MP, et al (2016) Non-invasive detection of 2-
hydroxyglutarate in IDH-mutated gliomas using two-dimensional localized correlation spectroscopy (2D L-COSY) at 7 Tesla. J Transl Med 14:274. doi: 10.1186/s12967-016-1035-1 
14. Li Y, Lafontaine M, Chang S, Nelson SJ (2018) Comparison between Short and Long 
Echo Time Magnetic Resonance Spectroscopic Imaging at 3T and 7T for Evaluating Brain Metabolites in Patients with Glioma. ACS Chem Neurosci 9:130 –137. doi: 
10.1021/acschemneuro.7b00286 
15. Patel AJ, Suki D, Hatiboglu MA, et al (2010) Factors influencing the risk of local 
recurrence after resection of a single brain metastasis. J Neurosurg 113:181–189. doi: 10.3171/2009.11.JNS09659 
16. Kaye AH, Laws ER (2001) Brain Tumors. Gulf Professional Publishing 
Proprietary Information of MD Anderson
Protocol No: 2019-1032 
Version No: 10 
Version Date:  August 25, 2023 
27 
 17. Mayr NA, Yuh WT, Muhonen MG, et al (1994) Cost- effectiveness of high -dose MR 
contrast studies in the evaluation of brain metastases. AJNR Am J Neuroradiol 15:1053–
1061. 
18. Barajas RF, Cha S (2012) Imaging diagnosis of brain metastasis. Prog Neurol Surg 25:55–
73. doi: 10.1159/000331174 
19. Smith TE, Steven A, Bagert BA (2019) Gadolinium Deposition in Neurology Clinical 
Practice. Ochsner J 19:17 –25. doi: 10.[ZIP_CODE]/toj.18.0111 
20. Caraiani C, Dong Y, Rudd AG, Dietrich CF (2018) Reasons for inadequate or incomplete 
imaging techniques. Med Ultrason 20:498–507. doi: 10.[ZIP_CODE]/mu-1736 
21. Beck ES, Sati P, Sethi V, et al (2018) Improved Visualization of Cortical Lesions in 
Multiple Sclerosis Using 7T MP2RAGE. AJNR Am J Neuroradiol 39:459–466. doi: 10.3174/ajnr.A5534 
22. Warntjes JBM, Leinhard OD, West J, Lundberg P (2008) Rapid magnetic resonance 
quantification on the brain: Optimization for clinical usage. Magn Reson Med 60:320–329. doi: 10.1002/mrm.[ZIP_CODE] 
23. Kvernby S, Warntjes MJB, Haraldsson H, et al (2014) Simultaneous three-dimensional 
myocardial T1 and T2 mappi[INVESTIGATOR_38162] 3D-QALAS. J Cardiovasc Magn Reson 16:102. doi: 10.1186/s12968-014-0102-[ADDRESS_40080], Tsiouris AJ, Johnson AN, et al (2017) Synthetic MRI for Clinical 
Neuroimaging: Results of the Magnetic Resonance Image Compi[INVESTIGATOR_344] (MAGiC) Prospective, Multicenter, Multireader Trial. AJNR Am J Neuroradiol 38:1103–1110. doi: 10.3174/ajnr.A5227 
25. Blystad I, Warntjes JBM, Smedby O, et al (2012) Synthetic MRI of the brain in a clinical 
setting. Acta Radiol 53:1158–1163. doi: 10.1258/ar.2012.120195 
26. Hagiwara A, Hori M, Suzuki M, et al (2016) Contrast- enhanced synthetic MRI for the 
detection of brain metastases. Acta Radiol Open 5:2058460115626757. doi: 10.1177/2058460115626757 
27. Dula AN, Asche EM, Landman BA, et al (2011) Development of chemical exchange 
saturation transfer at 7 T. Magn Reson Med 66:831–838. doi: 10.1002/mrm.[ZIP_CODE] 
28. Moseley ME, Kucharczyk J, Mintorovitch J, et al (1990) Diffusion-weighted MR imaging 
of acute stroke: correlation with T2 -weighted and magnetic susceptibility -enhanced MR 
imaging in cats. AJNR Am J Neuroradiol 11:423–429. 
29. Sener RN (2001) Diffusion MRI: apparent diffusion coefficient (ADC) values in the 
normal brain and a classification of brain disorders based on ADC values. Computerized Medical Imaging and Graphics 25:299–326. doi: 10.1016/S0895-6111(00)[ZIP_CODE]-5 
Proprietary Information of MD Anderson
Protocol No: 2019-1032 
Version No: 10 
Version Date:  August 25, 2023 
28 
 30. Taylor W (2003) Diffusion tensor imaging: background, potential, and utility in 
psychiatric research. Biological Psychiatry. doi: 10.1016/S0006-3223(03)[ZIP_CODE]-8 
31. Wang X -C, Lei Y, Wang L, et al (2018) Diffusion Kurtosis Imaging Reflects Glial 
Fibrillary Acidic Protein (GFAP), Topo IIα, and O⁶-Methylguanine- DNA 
Methyltransferase (MGMT) Expression in Astrocytomas. Med Sci Monit 24:8822–8830. 
doi: 10.[ZIP_CODE]/MSM.911631 
32. Jensen JH, Helpern JA (2010) MRI quantification of non-Gaussian water diffusion by 
[CONTACT_38189]. NMR Biomed 23:698–710. doi: 10.1002/nbm.1518 
33. Fujima N, Sakashita T, Homma A, et al (2018) Utility of a Hybrid IVIM-DKI Model to 
Predict the Development of Distant Metastasis in Head and Neck Squamous Cell Carcinoma Patients. Magn Reson Med Sci 17:21–27. doi: 10.2463/mrms.mp.2016-0136 
34. Falk Delgado A, Nilsson M, van Westen D, Falk Delgado A (2018) Glioma Grade 
Discrimination with MR Diffusion Kurtosis Imaging: A Meta -Analysis of Diagnostic 
Accuracy. Radiology 287:119–127. doi: 10.1148/radiol.[PHONE_612] 
35. Yang X, Holmes MJ, Newton AT, et al (2012) A Comparison of Distributional 
Considerations with Statistical Analysis of Resting State fMRI at 3T and 7T. Proc SPIE Int Soc Opt Eng 8314:831416. doi: 10.1117/12.911307 
36. (2019) Characterizing Microstructural Tissue Properties in Multiple Sclerosis with 
Diffusion MRI at 7 T and 3 T: The Impact of the Experimental Design. Neuroscience 403:17–26. doi: 10.1016/j.neuroscience.2018.03.048 
37. Fink JR, Muzi M, Peck M, Krohn KA (2015) Multimodality Brain Tumor Imaging: MR 
Imaging, PET, and PET/MR Imaging. J Nucl Med 56:1554–1561. doi: 10.2967/jnumed.113.131516 
38. Boxerman JL, Ellingson BM, Jeyapalan S, et al (2017) Longitudinal DSC- MRI for 
Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High- grade 
Glioma. Am J Clin Oncol 40:228–234. doi: 10.1097/COC.0000000000000156 
39. Chaskis C, Stadnik T, Michotte A, et al (2006) Prognostic value of perfusion-weighted 
imaging in brain glioma: a prospective study. Acta Neurochir 148:277–85– discussion 285. doi: 10.1007/s00701-005-0718-9 
40. Barajas RF Jr, Chang JS, Segal MR, et al (2009) Differentiation of Recurrent 
Glioblastoma Multiforme from Radiation Necrosis after External Beam Radiation Therapy with Dynamic Susceptibility -weighted Contrast-enhanced Perfusion MR Imaging 
1. Radiology 253:486–496. doi: 10.1148/radiol.[PHONE_613] 
41. Boxerman JL, Zhang Z, Safriel Y, et al (2013) Early post-bevacizumab progression on 
contrast -enhanced MRI as a prognostic marker for overall survival in recurrent 
glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study. Neuro-oncology 15:945–954. doi: 10.1093/neuonc/not049 
Proprietary Information of MD Anderson
Protocol No: 2019-1032 
Version No: 10 
Version Date:  August 25, 2023 
29 
 42. Boxerman JL, Hamberg LM, Rosen BR, Weisskoff RM (1995) MR contrast due to 
intravascular magnetic susceptibility perturbations. Magn Reson Med 34:555–566. 
43. Kiselev VG, Strecker R, Ziyeh S, et al (2005) Vessel size imaging in humans. Magn 
Reson Med 53:553–563. doi: 10.1002/mrm.[ZIP_CODE] 
44. Kang H- Y, Xiao H-L, Chen J-H, et al (2016) Comparison of the Effect of Vessel Size 
Imaging and Cerebral Blood Volume Derived from Perfusion MR Imaging on Glioma 
Grading. AJNR Am J Neuroradiol 37:51–57. doi: 10.3174/ajnr.A4477 
45. Zaiss M, Windschuh J, Paech D, et al (2015) Relaxation- compensated CEST -MRI of the 
human brain at 7T: Unbiased insight into NOE and amide signal changes in human glioblastoma. NeuroImage 112:180–188. doi: 10.1016/j.neuroimage.2015.02.040 
46. Cai K, Singh A, Poptani H, et al (2015) CEST signal at 2ppm (CEST@2ppm) from Z-
spectral fitting correlates with creatine distribution in brain tumor. NMR Biomed 28:1–8. doi: 10.1002/nbm.3216 
47. Zhou J, Payen J-F, Wilson DA, et al (2003) Using the amide proton signals of intracellular 
proteins and peptides to detect pH effects in MRI. Nat Med 9:1085–1090. doi: 10.1038/nm907 
48. Zhou J, Tryggestad E, Wen Z, et al (2011) Differentiation between glioma and radiation 
necrosis using molecular magnetic resonance imaging of endogenous proteins and peptides. Nat Med 17:130–134. doi: 10.1038/nm.2268 
49. Togao O, Yoshiura T, Keupp J, et al (2014) Amide proton transfer imaging of adult 
diffuse gliomas: correlation with histopathological grades. Neuro-oncology 16:441–448. doi: 10.1093/neuonc/not158 
50. Williams DS, Detre JA, Leigh JS, Koretsky AP (1992) Magnetic resonance imaging of 
perfusion using spin inversion of arterial water. Proc Natl Acad Sci [LOCATION_003] 89:212–216. doi: 10.1073/pnas.89.1.212 
51. Wolf RL, Detre JA (2007) Clinical Neuroimaging Using Arterial Spin -Labeled Perfusion 
Magnetic Resonance Imaging. Neurotherapeutics 4:346–359. doi: 10.1016/j.nurt.2007.04.005 
52. Liebeskind DS (2003) Collateral Circulation. Stroke 34:2279–2284. doi: 
10.1161/01.STR.[PHONE_614].[ZIP_CODE].06 
53. Calamante F, Williams SR, van Bruggen N, et al (1996) A Model for Quantification of 
Perfusion in Pulsed Labelling Techniques. NMR Biomed 9:79–83. doi: 10.1002/(SICI)1099-1492(199604)9:2<79::AID-NBM399>3.0.CO;2-4 
54. Warmuth C, Günther M, Zimmer C (2003) Quantification of Blood Flow in Brain 
Tumors: Comparison of Arterial Spin Labeling and Dynamic Susceptibility-weighted 
Proprietary Information of MD Anderson
Protocol No: 2019-1032 
Version No: 10 
Version Date:  August 25, [ADDRESS_40081]-enhanced MR Imaging1. Radiology 228:523–532. doi: 
10.1148/radiol.[PHONE_615] 
55. Bokkers RP, Bremmer JP, van Berckel BN, et al (2009) Arterial Spin Labeling Perfusion 
MRI at Multiple Delay Times: A Correlative Study with H215O Positron Emission Tomography in Patients with Symptomatic Carotid Artery Occlusion:. Journal of Cerebral Blood Flow & Metabolism 30:222–229. doi: 10.1038/jcbfm.2009.204 
56. Dury RJ, Falah Y, Gowland PA, et al (2019) Ultra-high- field arterial spin labelling MRI 
for non- contrast assessment of cortical lesion perfusion in multiple sclerosis. Eur Radiol 
29:2027–2033. doi: 10.1007/s00330-018-5707-5 
 
10 APPENDICES  
 
Appendix A - MRI Safety Questionnaire)  
Appendix B - Re ferral Questionnaire for MDACC  
Appendix C - UTMDACC Division of Diagnostic Imaging Policy # 3.00: Imaging of Healthy 
Volunteers for Quality Assurance/Improvement and Technical Development. 
Proprietary Information of MD Anderson